Lucid Diagnostics Inc. (LUCD)
NASDAQ: LUCD · Real-Time Price · USD
0.843
-0.004 (-0.50%)
At close: Jan 17, 2025, 4:00 PM
0.866
+0.023 (2.73%)
After-hours: Jan 17, 2025, 7:19 PM EST
Lucid Diagnostics Revenue
Lucid Diagnostics had revenue of $1.17M in the quarter ending September 30, 2024, with 49.68% growth. This brings the company's revenue in the last twelve months to $4.19M, up 179.27% year-over-year. In the year 2023, Lucid Diagnostics had annual revenue of $2.43M with 544.03% growth.
Revenue (ttm)
$4.19M
Revenue Growth
+179.27%
P/S Ratio
9.35
Revenue / Employee
$59,843
Employees
70
Market Cap
46.73M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
LUCD News
- 7 days ago - Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume - PRNewsWire
- 4 weeks ago - Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - PRNewsWire
- 4 weeks ago - Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters - PRNewsWire
- 5 weeks ago - Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication - PRNewsWire
- 6 weeks ago - Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones - PRNewsWire
- 2 months ago - Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test - PRNewsWire
- 2 months ago - Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - PRNewsWire
- 2 months ago - Lucid Diagnostics Inc. (LUCD) Q3 2024 Earnings Call Transcript - Seeking Alpha